德明利（001309）(001309.SZ)发布公告，公司董事会决定根据公司《2025年股票期权激励计划(草案)》 的相关规定以及公司2025年第三次临时股东大会的授权，董事会认为公司2025年股票期权激励计划的首 次授予条件已经成就，决定以2025年9月22日为授予日，向符合2025年股票期权激励计划授予条件的首 次授予的294名激励对象授予股票期权386.3万份，授予价格为80.99元/份。 ...

2025年8月25日，深圳市捷顺科技实业股份有限公司召开会议，审议通过注销部分股票期权议案。鉴于 2024年股票期权激励计划中5名激励对象离职，公司注销其已获授但尚未行权的股票期权192,500份。截 至公告披露日，已完成注销手续。首次授予激励对象总人数由200名调为195名，尚未行权的股票期权数 量由9,319,800份调至9,127,300份。预留授予激励对象及尚未行权期权数量不变。本次注销符合相关规 定，对公司无实质影响。 ...

Core Points - Weichuang Electric (688698.SH) announced the achievement of the initial grant conditions for the 2025 stock option incentive plan [1] - The company held its third board meeting on September 12, 2025, to review and approve the proposal for the initial grant of stock options to the incentive recipients [1] - A total of 2.57 million stock options will be granted at an exercise price of 59.18 yuan per option to 151 incentive recipients [1]

Group 1 - On September 5, 2025, Junshi Biosciences (688180) closed at 48.0 yuan, up 7.38%, with a turnover rate of 3.3% and a trading volume of 252,900 shares, amounting to a transaction value of 1.173 billion yuan [1] - On the same day, there was a net inflow of 12.36 million yuan from institutional investors, accounting for 1.05% of the total transaction value, while retail investors saw a net inflow of 13.08 million yuan, also representing 1.11% of the total [1][4] - A block trade occurred on September 5, with a transaction amount of 47.66 million yuan [2][4] Group 2 - Junshi Biosciences will hold its first extraordinary general meeting of shareholders on September 26, 2025, to review several proposals, including the election of Yang Jin as an independent non-executive director and the introduction of a stock option incentive plan for 2025 [3][4] - The company plans to issue 41 million H-shares, increasing its registered capital from 985,689,871 yuan to 1,026,689,871 yuan, and will abolish the supervisory board, transferring its duties to the audit committee of the board [2][4] - The company announced that its anti-IL-17A monoclonal antibody JS005 has achieved the primary endpoint in a Phase III clinical trial for moderate to severe plaque psoriasis, with plans to submit a marketing authorization application soon [4][7]

Core Points - The company has reviewed and approved the 2025 Stock Option Incentive Plan, confirming the eligibility of the incentive recipients [1][2] - A total of 1,227,000 stock options will be granted to 266 incentive recipients, with the grant date set for September 4, 2025 [2] Summary by Sections - **Eligibility of Incentive Recipients** - The incentive recipients do not fall under any disqualifying conditions as outlined in the relevant regulations [1] - The recipients meet the qualifications set forth in the Securities Law and the Stock Option Incentive Management Measures [2] - **Approval and Compliance** - The board's Compensation and Assessment Committee has deemed the procedures and content of the incentive plan to be legal and compliant, supporting the company's sustainable development [2] - There are no circumstances that would harm the interests of the company or its shareholders [2]

Core Points - The company has approved the 2025 Stock Option Incentive Plan, which includes a list of eligible participants for stock options [1][2] - The Supervisory Board has confirmed that the selected participants meet the criteria set forth in relevant laws and regulations, ensuring their eligibility for the incentive plan [2] Group 1 - The 2025 Stock Option Incentive Plan was reviewed and found to comply with the laws and regulations, promoting the company's sustainable development [2] - A total of 266 participants will be granted 12.27 million stock options, with the grant date set for September 4, 2025 [2]

Group 1 - The company held its 12th meeting of the 4th Supervisory Board on September 4, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to grant stock options to incentive targets, confirming that the granting date aligns with regulations and that conditions for granting have been met [1][2] - Legal opinions regarding the stock option incentive plan were provided and published on September 5, 2025, confirming the legality of the actions taken [1]

Core Points - The company has approved the cancellation of 5.05 million stock options due to the departure of 6 incentive targets and unmet performance goals for the first exercise period [1][2] - The cancellation of stock options will not affect the company's total share capital or share structure, ensuring no harm to the interests of all shareholders, especially minority shareholders [2] - Following the adjustments, the number of incentive targets for the 2024 stock option plan has been reduced from 176 to 170, and the number of stock options granted but not yet exercisable has been adjusted from 19.6 million to 14.55 million [2]

证券简称：运机集团 证券代码：001288 四川省自贡运输机械集团股份有限公司 （草案） 四川省自贡运输机械集团股份有限公司 一、《四川省自贡运输机械集团股份有限公司 2025 年股票期权激励计划 （草案）》（以下简称"本激励计划"）由四川省自贡运输机械集团股份有限公司 （以下简称"公司"、"本公司"或"运机集团"）依据《中华人民共和国证券法》 《中华人民共和国公司法》《上市公司股权激励管理办法》（以下简称"管理办 法"）《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》（以下简称 "自律监管指南第 1 号"）及其他相关法律、法规、规章和规范性文件，以及 《四川省自贡运输机械集团股份有限公司公司章程》（以下简称"公司章程"）等 有关规定制订。 二、本次激励计划采取的激励工具为股票期权。股票来源为公司向激励对 象定向发行的公司 A 股普通股股票和/或从二级市场回购的公司 A 股普通股股 票。 四川省自贡运输机械集团股份有限公司 2025 年股票期权激励计划（草案） 声明 本公司及全体董事保证本计划及其摘要不存在虚假记载、误导性陈述或重 大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 本 ...

Group 1 - The core opinion of the article is that the Compensation and Assessment Committee of Guangdong Jushi Chemical Co., Ltd. has verified the list of incentive objects for the 2025 stock option incentive plan, confirming their eligibility under relevant laws and regulations [1][2]. - The committee has identified that the proposed incentive objects do not fall under any disqualifying conditions as outlined in the relevant legal frameworks, thus their qualifications are deemed legal and valid [2]. - The plan includes granting 1,200,000 stock options to 18 incentive objects, with an exercise price set at 14.95 yuan per option, with the reserved authorization date being September 3, 2025 [2]. Group 2 - The article outlines specific disqualifying conditions for incentive objects, including being recognized as inappropriate by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months, or having been subject to administrative penalties or market entry bans due to major violations [1]. - The committee's verification process adheres to the provisions of the Company Law, Securities Law, and other relevant regulations, ensuring compliance with the guidelines for stock option incentives [1][2].